Company RDI Project

Research and development of innovative pharmaceutical active substances and products with high added value in the areas of cardiology, oncology and central nervous system diseases.
START DATE: 2017-11-01

Target

In this project, Egis Pharmaceuticals has set the objectives of conducting research and development procedures on several pharmaceutical active substances and products in the areas of cardiology, oncology and central nervous system diseases.

Results

Results: 

● Three new products have been launched                
●10 marketable products/active ingredients reached laboratory or pilot-scale technology phase 
● Three new products’ prototypes have created 
● A national patent application has been filed to protect the innovation resulting from the project; there have been many peer-reviewed publications on the subject. 
● New medicines have been developed that can help to reduce the mortality rates in Hungary by contributing to the adequate treatment of the diseases that most affect the Hungarian population. 

Description

Information on the proposed project:

● Principal of the tender: National Research, Development and Innovation Office
● Title and code of the call for tender proposals: “Support of business RDI activities”, Vállalati KFI_16
● Title and ID of proposed project: “Research and development of innovative, value added APIs and formulated products for cardiovascular, oncological and CNS diseases”, KFI_16-1-2017-0170
● Submission date of proposal: 15/02/2017
● Date of decision about funding: 08/06/2017
● Granted amount and funding intensity in total: HUF 499,800,000 (52.5 %)
● Applicant: Egis Pharmaceuticals PLC
● Strategic partners:
          ● Eötvös Lorand Research Network, Research Centre for Natural Sciences, Medicinal Chemistry Research Group of the Institute of Organic Chemistry 
          ● H-ION Research, Development and Innovation Ltd. 
● Time period for project implementation: 01/11/2017 - 31/10/2019
● Total costs of the project: HUF 952,000,000   
● Own resources: HUF 452, 200,000

 

Details

    Contact details in relation to the project:
Beneficiary's name and contact
Egis Pharmaceuticals PLC
1106 Budapest, Keresztúri út 30-38.
Phone: 06-1-803-5555
https://hu.egis.health
Managing Authority's and Intermediate Body's name and contact
National Research, Development and Innovation Office
1077 Budapest, Kéthly Anna tér 1.
Phone: 06-01-795-9500
nkfialap@nkfih.gov.hu

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox